RETaliation - tackling rare resistance alterations to osimertinib

Matthew G. Krebs, Sanjay Popat

Research output: Contribution to journalComment/debatepeer-review


RET fusions occur as a rare mechanism of acquired resistance to osimertinib in epidermal growth factor receptor mutation (EGFRm) positive non-small cell lung cancer (NSCLC) patients. Inhibiting RET alongside osimertinib shows promising clinical activity but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings.
Original languageEnglish
Pages (from-to)2951-2953
Number of pages3
JournalClinical Cancer Research
Issue number16
Early online date14 Jun 2023
Publication statusPublished - 15 Aug 2023


Dive into the research topics of 'RETaliation - tackling rare resistance alterations to osimertinib'. Together they form a unique fingerprint.

Cite this